Chimeric Antigen Receptor T cells: Priming, Cytotoxicity and the immune synapse

Chimeric Antigen Receptor T cells: Priming, Cytotoxicity and the immune synapse

Chimeric Antigen Receptor T cells: Priming, Cytotoxicity and the immune synapse (#14)

Misty Jenkins ¹

Walter and Eliza Hall Institute, Parkville, VICTORIA, Australia

Chimeric antigen receptor T (CAR-T) cells have shown incredible promise in the clinic but applying this therapy as a ‘living drug’ to solid tumours comes with additional challenges and will require a deeper understanding of CAR T cell biology. Our lab investigates how triggering cells via alternative receptors influences cell fate. Firstly, I will explore the functional consequences of CAR-mediated signalling using a dual-specific CAR T cell, where the same cell was triggered via TCR or CAR and discuss the implications on the immune synapse. This study provides a mechanism for how CAR T cells can de-bulk large tumor burden quickly and may contribute to further refinement of CAR design for enhancing the quality of signalling and programming of the T cell. Secondly, I will provide a rationale for exploring the role of CAR T cell priming on influencing T cell fate, including T cell proliferation and survival.

#ASI2017QLD

Authors contributing to this presentation.

Jenkins, M

Misty Jenkins is a NHMRC fellow and laboratory head in the Immunology Division at Walter and Eliza Hall Institute for Medical Research, where she researches cellular immunology and cancer immunotherapy. Misty leads the immunotherapy program within the Brain Cancer Centre and is dedicated to developing new treatments for brain cancer patients. Misty studied her PhD in Immunology at The University of Melbourne, followed by postdoctoral positions at The Universities of Cambridge and Oxford, and The Peter MacCallum Cancer Centre in Melbourne. Misty has a long-standing interest in CD8+ T cells and her research program researches the use of T cell immunotherapy for brain cancer. A/Prof Jenkins was awarded the L’Oreal for Women in Science Fellowship (2013), was Tall Poppy of the year (2015), was awarded the Westpac/Australian Financial Review Top100 Women of Influence award (2016) and was inducted onto the Victorian Honour Roll of Women in 2020. In addition to her research career, A/Prof Jenkins is experienced in governance and is a Board Director for Monash Health, Co-Chair of the Indigenous Health Medical Research Future Fund, and advises the Victorian Government on Health and Medical Research strategy.

Chimeric Antigen Receptor T cells: Priming, Cytotoxicity and the immune synapse (#14)

Add notes

Jenkins, M

Login